IntegenX Announces Early Access Partnership for Its RapidHIT(TM) 200 Human DNA Identification System

PLEASANTON, CA and COVENTRY, UNITED KINGDOM--(Marketwire - June 20, 2011) - IntegenX Inc. (IXI) today announced an Early Access Program for its RapidHIT™ 200 Human Identification System. The Early Access program is designed to provide IXI’s global partners with advance product access and training. Early Access partners will receive pre-production prototypes of the RapidHIT 200 instrument, disposable reagent cartridges and application priority in the US and abroad.

Key Forensics Sciences Ltd (KFS) has agreed to become the first international partner of IntegenX’s RapidHIT 200 Early Access Program. The partnership will allow KFS to optimize and use the RapidHIT 200 instrument and disposable cartridge system for commercial forensic services in the UK. Key objectives of the partnership include validating the RapidHIT System and introducing fast human identification services to police forces in England and Wales.

The mobile, self-contained, fully integrated RapidHIT 200 Human Identification System automates and accelerates the process of producing standardized DNA profiles from mouth swabs and other human tissue samples. In less than 2 hours, the RapidHIT system produces human DNA profiles compatible with the UK National DNA Database (NDNAD) and the US National DNA Index System (NDIS). DNA profiles generated by the RapidHIT System can be used to search the NDNAD or NDIS databases for matches or to expand those databases. Numerous local, state, national, and international law enforcement and security agencies use DNA-based human identification to make informed decisions regarding the arrest, detention, or release of suspects to protect national borders, and to analyze crime scene evidence.

“KFS believes that the RapidHIT 200 System will revolutionize the provision of DNA profiles, enabling samples to be profiled within two hours at police custody suites within the UK,” said Paul Hackett, KFS Managing Director. “This device has the potential to transform the way KFS conducts DNA analysis by delivering unprecedented improvements in turnaround times, providing DNA testing away from the laboratory such as at the scene of crime, and reducing overall forensic supply chain costs,” added Mr. Hackett.

“The Early Access Program enables our partners to begin using RapidHIT technology for fast, DNA-based human identification prior to next year’s commercial launch of the RapidHIT 200 System,” explained Stevan Jovanovich, President and Chief Executive Officer of IntegenX. “We are delighted to be working with KFS as they provide human identification services for UK custody suites and time-sensitive criminal and terrorism investigations. The feedback we receive from KFS will help us prioritize our pre-launch activities for the RapidHIT System and refine our DNA forensics product development roadmap.”

About Key Forensic Services Ltd.
Key Forensic Services Ltd. (KFS) is a privately-held Coventry, UK based company that delivers forensic science solutions to the criminal justice system and private sector clients in the United Kingdom and Internationally. Its traditional forensic services include search and recovery of submissions for DNA profiling; document examinations; footwear marks screening; determination of weight, identification, and purity of drugs, as well as examination of items recovered from a crime scene for drug traces; forensic firearms training and awareness; gunshot residue examination; and evaluation and reporting of fingerprint casework. The company also offers digital forensic services, such as mobile phone examination, hex dumping, cell site analysis, computer forensics, forensic video analysis, and forensic audio services; and supplies forensic kits and packaging supplies. In addition, it provides professional forensic consultancy services for criminal defense lawyers; specialist custom collection and delivery service to police forces; and training and consultancy services. For more information, please visit www.keyforensic.co.uk.

About IntegenX Inc.
IntegenX Inc. (IXI), headquartered in Pleasanton, CA, is a privately-held company that designs, manufactures, and markets solutions for DNA and RNA sample preparation laboratory workflows. IntegenX’s products eliminate the most acute pain points affecting researchers, laboratory workers and field based personnel. IntegenX’s microfluidics technology platforms integrate advanced fluidics and robotic capabilities to prepare samples for DNA and RNA sequencing and to produce sample-to-answer performance for DNA-based forensics and human identity (HID) testing, next generation sequencing, biodefense, and molecular diagnostics applications. For more information, please visit www.integenx.com.